Anticancer drug screening test with LDH in nude mouse bearing bone and soft part sarcoma.
With the use of human LDH as a marker, growth and remission of four human osteosarcomas (KOS-1, KOS-2, KOS-3, OST) and a malignant fibrous histiocytoma (KMF) transplanted into nude mice were monitored during chemotherapies (Adriamycin [doxorubicin], cisplatin, mitomycin C, cyclophosphamide and vincristine). Four osteosarcomas were effectively treated with Adriamycin and cisplatin, and KMF was treated with Adriamycin, cisplatin, and mitomycin C. Changes in human LDH levels paralleled changes in tumor size and these could be used to predict the death of the animals due to tumor (P less than 0.01). Furthermore, the enzyme increased transiently after administration of the effective drugs.
Nakamura
T
T
Kitagawa
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D004353:Drug Evaluation, Preclinical; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D007527:Isoenzymes; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D012516:Osteosarcoma / Q000188:drug therapy* / Q000201:enzymology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013997:Time Factors; D014183:Transplantation, Heterologous
D000970:Antineoplastic Agents; D007527:Isoenzymes; D007770:L-Lactate Dehydrogenase